132 related articles for article (PubMed ID: 2695292)
1. Structures and activities of activated abl oncogenes.
Risser R; Holland GD
Curr Top Microbiol Immunol; 1989; 147():129-53. PubMed ID: 2695292
[No Abstract] [Full Text] [Related]
2. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.
Engelman A; Rosenberg N
Mol Cell Biol; 1990 Aug; 10(8):4365-9. PubMed ID: 2164639
[TBL] [Abstract][Full Text] [Related]
3. Oncogenes. The beginning of the molecular description of a cancer.
Baltimore D
Cell Biophys; 1986 Dec; 9(1-2):17-31. PubMed ID: 2436791
[No Abstract] [Full Text] [Related]
4. Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Shore SK; Bogart SL; Reddy EP
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6502-6. PubMed ID: 2168550
[TBL] [Abstract][Full Text] [Related]
5. Activation of the abl oncogene and its involvement in chromosomal translocations in human leukemia.
Rosson D; Reddy EP
Mutat Res; 1988 May; 195(3):231-43. PubMed ID: 3129652
[TBL] [Abstract][Full Text] [Related]
6. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.
Rosenbaum H; Harris AW; Bath ML; McNeall J; Webb E; Adams JM; Cory S
EMBO J; 1990 Mar; 9(3):897-905. PubMed ID: 2155783
[TBL] [Abstract][Full Text] [Related]
7. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
Franz WM; Berger P; Wang JY
EMBO J; 1989 Jan; 8(1):137-47. PubMed ID: 2496972
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of an Abelson virus-transformed immature B precursor cell line under the expression of tyrosine kinase activity of v-abl oncogene product.
Maeda T; Owada MK; Sugiyama H; Miyake S; Tani Y; Ogawa H; Oka Y; Komori T; Soma T; Kishimoto S
Cell Differ; 1987 Apr; 20(4):263-9. PubMed ID: 2438051
[TBL] [Abstract][Full Text] [Related]
9. A common cellular pathway for v-mos and v-Ki-ras is not required for v-Ki-ras-induced tumorigenicity in a nonmalignant, v-mos-expressing revertant cell.
Gerfaux J; Sergiescu D; Hamelin R; Joret AM; Lallemand C
Mol Carcinog; 1990; 3(2):103-13. PubMed ID: 2161237
[TBL] [Abstract][Full Text] [Related]
10. Introduction of v-abl oncogene induces monocytic differentiation of an IL-3-dependent myeloid progenitor cell line.
Keller JR; Ruscetti SK; Ruscetti FW
Oncogene; 1990 Apr; 5(4):549-55. PubMed ID: 2158039
[TBL] [Abstract][Full Text] [Related]
11. The Abelson murine leukemia virus oncogene.
Goff SP
Proc Soc Exp Biol Med; 1985 Sep; 179(4):403-12. PubMed ID: 2991935
[No Abstract] [Full Text] [Related]
12. Germ-line transmission of a c-abl mutation produced by targeted gene disruption in ES cells.
Schwartzberg PL; Goff SP; Robertson EJ
Science; 1989 Nov; 246(4931):799-803. PubMed ID: 2554496
[TBL] [Abstract][Full Text] [Related]
13. Viral oncogene expression during differentiation of Abelson virus-infected murine promonocytic leukemia cells.
Hines DL
Cancer Res; 1988 Apr; 48(7):1702-7. PubMed ID: 2832050
[TBL] [Abstract][Full Text] [Related]
14. The viral and cellular forms of the Abelson (abl) oncogene.
Rosenberg N; Witte ON
Adv Virus Res; 1988; 35():39-81. PubMed ID: 2852893
[TBL] [Abstract][Full Text] [Related]
15. abl genes.
Ramakrishnan L; Rosenberg N
Biochim Biophys Acta; 1989 Dec; 989(2):209-24. PubMed ID: 2532040
[No Abstract] [Full Text] [Related]
16. Role of the ABL oncogene tyrosine kinase activity in human leukaemia.
Pendergast AM; Witte ON
Baillieres Clin Haematol; 1987 Dec; 1(4):1001-20. PubMed ID: 3332851
[TBL] [Abstract][Full Text] [Related]
17. Structure and origins of the HZ2-feline sarcoma virus.
Bergold PJ; Wang JY; Hardy WD; Littau V; Johnson E; Besmer P
Virology; 1987 Jun; 158(2):320-9. PubMed ID: 2884777
[TBL] [Abstract][Full Text] [Related]
18. v-erbA cooperates with bFGF in neuroretina cell transformation.
Garrido C; Li RP; Samarut J; Gospodarowicz D; Saule S
Virology; 1993 Feb; 192(2):578-86. PubMed ID: 7678474
[TBL] [Abstract][Full Text] [Related]
19. Cell transformation by dbl oncogene.
Zangrilli D; Eva A
Methods Enzymol; 1995; 256():347-58. PubMed ID: 7476452
[No Abstract] [Full Text] [Related]
20. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Lugo TG; Pendergast AM; Muller AJ; Witte ON
Science; 1990 Mar; 247(4946):1079-82. PubMed ID: 2408149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
